Please select your page


Montreal, Canada – May 28, 2014 - Knight Therapeutics Inc. ("Knight") (TSX: GUD) today reported its financial results for the quarter ended March 31, 2014.

Management’s discussion and analysis of financial condition and results of operations for the first quarter 2014 Download / Print PDF

Knight Therapeutics financial results – Q1 2014 Download / Print PDF

1st Quarter 2014 Highlights

• Listed on TSX-V on February 28, 2014 and began trading on TSX-V under the ticker symbol GUD.V on March 3, 2014. 

• Entered into and completed a private placement for a total of $75 million in gross proceeds. Knight issued 21,428,580 special warrants (the “Special Warrants”) at a price of $3.50 per Special Warrant for aggregate gross proceeds to Knight of $75 million. 3487911 Canada Inc., an entity controlled by the company’s President and Chief Executive Officer, purchased 6,052,739 Special Warrants under the offering for approximately $21 million.

• Received U.S. FDA approval for Impavido®(miltefosine) for the treatment of Visceral, Mucosal and Cutaneous Leishmaniasis.

• In conjunction with receiving U.S. FDA approval, Knight was awarded a Priority Review Voucher which entitles the bearer to a priority review for any product and may be sold.

Subsequent to the Quarter

• Entered into and completed a second private placement for total of $180 million in gross proceeds. Knight issued 34,300,000 additional special warrants at a price of $5.25 with substantially the same terms as the Special Warrants for a total of $180 million in gross proceeds. 3487911 Canada Inc. purchased 7,620,000 of the 34,300,000 additional special warrants. 

• Entered into an arrangement on April 14, 2014 with Medicure, a specialty pharmaceutical company, under which Knight will provide advisory services to help advance Medicure's U.S. specialty pharmaceutical business. 

• Began trading on Toronto Stock Exchange on April 29, 2014 under the ticker symbol GUD and de-listed from TSX Venture Exchange.

• Announced On May 1, 2014 that the company had engaged Genesys Capital Management Inc. to assist Knight with its business development efforts. The mandate included lending money on a secured basis to emerging biotechnology and specialty pharmaceutical companies in order to gain access to innovative products for the Canadian market.

• Effective today, Mark A. Beaudet has resigned from the Knight Board of Directors. The company would like to thank Mr. Beaudet for his contributions to Knight. The Board intends to replace Mr. Beaudet with a new director.

First Quarter 2014 Financial Results Reported in Canadian Dollars 

The company’s financial statements for the period ended March 31, 2014 have been prepared in accordance with IAS 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB).

The company reported quarterly Revenues of $1,441, a Net Loss of $75,742, $75,449,376 of cash and 22,036,060 common shares outstanding as at March 31, 2014.

“Knight won’t rest until it is at least as successful as Paladin. Now that we are well capitalized, we can focus on strategy execution” said Jonathan Ross Goodman, President and CEO of Knight Therapeutics Inc. 

Conference Call Notice 

Knight will host a conference call to discuss its first quarter results today at 10:00 am ET. Investors and other interested parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. For more information about Knight Therapeutics Inc., please visit the company's website at or at


Jeffrey Kadanoff 
Chief Financial Officer
Knight Therapeutics Inc.

Tel: 514-484-4483
Fax: 514-481-4116
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the company’s final application for listing on the TSX Venture Exchange and in two short form prospectuses which can be found on SEDAR at, which investors should consult for additional information. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. 

Neither TSX nor its Regulation Services Providers (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Buy now

You can now buy this awesome Joomla Theme directly on Themeforest for a really low price for this awesome and stunning Joomla product!

Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nulla vitae elit libero, a pharetra augue.




Please login using your credentials recived by email when you register.

  or   Create an account

Forgot your password? |  Forgot your username?


Register now

I'm a small Introtext for the Register Module, I can be set in the Backend of the Joomla WS-Register Module.

  or   Login